GABRD is the delta subunit of the GABA (Gamma-Aminobutyric Acid) A-type receptor. GABA is the major inhibitory neurotransmitter in the mammalian brain, and its action on GABA-A receptors can be modulated by various drugs such as barbiturates, benzodiazepines, steroids, or alcohol. The role of GABRD in various cancers has been studied. For instance, in Colon Adenocarcinoma (COAD), the expression of GABRD is significantly elevated and associated with advanced clinical staging. High GABRD expression correlates with shorter overall survival and progression-free survival in patients, making it an independent predictor of overall survival. In Breast Cancer, GABRD promotes breast cancer progression through CDK1-dependent cell cycle regulation, with significantly elevated expression levels in tumor tissues and correlation with advanced tumor progression. Additionally, GABRD is considered prognostic in Bladder Urothelial Carcinoma and Clear Cell Renal Cell Carcinoma. In Gastric Cancer (GC), high expression levels of GABRD mRNA are associated with poor prognosis. The function of GABRD in proliferation, invasion, and apoptosis experiments has been assessed, indicating that GABRD plays a significant role in GC cell proliferation and invasion and is correlated with poor prognosis, suggesting that GABRD may be a potential therapeutic target for gastric cancer.